XNAS · EYPT
+6.28% · +$0.8800 · Vol 1.6M
Market closed · last close 4:00 PM ET · price as of 19:09:11 ET
EyePoint, Inc. Common Stock

EyePoint, Inc. Common Stock

LABORATORY ANALYTICAL INSTRUMENTS
$14.89
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is EYPT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for EYPT are being assembled.
About EyePoint, Inc. Common Stock
LABORATORY ANALYTICAL INSTRUMENTS
Listed since
2005
Employees
214
Country
US

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$14.00
Day high
$14.99
Day low
$13.97
Previous close
$14.01
52W high
$14.99
-0.67% from high
52W low
$12.20
96% of range
Market cap
$1.2B
EPS
$-3.3400
Shares out
83.8M
Volume
1.6M
VWAP
$14.71
Price history computed in-house
1W
+3.98%
1M
+19.69%
SMA 50 $13.67 · above
SMA 200 $13.67 · above
52W position 96%
Veridion warehouse edge

Warehouse intelligence for EYPT.

Veridion Score
33
0: 321: 432: 533: 104: 825: 50
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

EYPT insider activity

EyePoint, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for EYPT.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

EYPT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EYPT in this window.
Lobbying spend

EYPT lobbying filings, year to date.

Registered lobbying filings matched to EyePoint, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EYPT in this window.
Latest news · EYPT
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for EYPT.
Options
Sovereign unlock shows live options positioning for EYPT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.